CVKD Cadrenal Therapeutics Inc: שולי רווח נקי ממכירות

Cadrenal Therapeutics Inc - לוגו גרפי של המנפיק CVKD

The net profitability of turnover dynamics displayed on GURU.Markets indicates current volatility, where 0.00 determines this parameter level. The stability of Cadrenal Therapeutics (CVKD) is limited by a lack of commercial sales and a dependence on grants. Efficiency is increasing through cloud automation of anticoagulant test collection, however, the expansion of the drug pipeline is currently only increasing specific research costs.

שיעור רווח נקי Cadrenal Therapeutics Inc (CVKD): לתקופה 28.04.2023 - 20.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Cadrenal Therapeutics, Inc (CVKD)

- שער מניה ותחזית מחירי מומחים:
ניתוח ראשוני של החברה:Cadrenal Therapeutics
מוצר המיוצר על ידי Cadrenal Therapeutics Inc.

Cadrenal Therapeutics (CVKD) maintains a specific niche within the US biopharmaceutical sector. This indicator determines the share of final profit in every dollar of revenue, measuring the fundamental resilience of the business. Investors utilize the net profit per unit of revenue metric to evaluate cost management efficiency. Given the outsourcing of molecule synthesis through CDMO partners, this metric reflects the actual cost of development. This chart captures the company's ability to convert scientific potential into financial results.